Feb-16 -

Leukemia Group

EORTC / GIMEMA 060661 – Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)

EORTC and GIMEMA found the addition of clofarabine to the standard first-phase treatment lead to higher response rates and prolonged survival in patients with intermediate/high-risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).


Go to Top